A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of REGN668 Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to learn more about a new study drug, REGN668. It is being used for the treatment of atopic dermatitis. The main purposes of this study are to help determine how well different doses (amounts) of the study drug work to treat eczema, and how the body reacts to the study drug.
1. Male or female, 18 years or older
2. Chronic Atopic dermatitis present for at least 3 years
3. Willing and able to comply with all clinic visits and study-related procedures
4. Able to understand and complete study-related questionnaires
18 - No limit
Healthy Volunteers Needed
Duration of Participation
Regeneron Pharmaceuticals, Inc.
50 dollars for each visit